Reduction of lipoprotein(a) with proprotein convertase subtilisin/kexin type 9 inhibitor as a potential contributor to modulating coronary inflammatory activity: insights from serial pericoronary adipose tissue analysis

被引：2
|
作者：
Kitahara, Satoshi [1 ]
Kataoka, Yu [1 ]
Miura, Hiroyuki [1 ]
Noguchi, Teruo [1 ]
机构：
[1] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷 / 16期
关键词：
D O I：
10.1093/eurheartj/ehab882
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1597 / 1597
页数：1
相关论文
共 50 条
  • [41] Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials
    Atia, Ahmed
    Aboeldahab, Heba
    Wageeh, Ahmed
    Elneny, Mohamed
    Elmallahy, Mohamed
    Elawfi, Bashaer
    Aboelkhier, Menna M.
    Elrosasy, Amr
    Abdelwahab, Maya Magdy
    Sayed, Somaya
    Abdelaziz, Ahmed
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2024, 24 (01) : 83 - 102
  • [42] Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children
    Girona, Josefa
    Rodriguez-Borjabad, Celia
    Ibarretxe, Daiana
    Heras, Mercedes
    Amigo, Nuria
    Feliu, Albert
    Masana, Luis
    Plana, Nuria
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (01) : 211 - 218
  • [43] Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials
    Ahmed Atia
    Heba Aboeldahab
    Ahmed Wageeh
    Mohamed Elneny
    Mohamed Elmallahy
    Bashaer Elawfi
    Menna M. Aboelkhier
    Amr Elrosasy
    Maya Magdy Abdelwahab
    Somaya Sayed
    Ahmed Abdelaziz
    American Journal of Cardiovascular Drugs, 2024, 24 : 83 - 102
  • [44] Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis
    Song, Ruohong
    Li, Jinsong
    Xiong, Yan
    Huang, Hui
    Liu, Xiaojian
    Li, Qiyong
    MEDICINE, 2024, 103 (22) : E38360
  • [45] Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents
    Maharjan, Binita
    Payne, Daniel T.
    Ferrarese, Irene
    Lupo, Maria Giovanna
    Shrestha, Lok Kumar
    Hill, Jonathan P.
    Ariga, Katsuhiko
    Rossi, Ilaria
    Shrestha, Shyam Sharan
    Panighel, Giovanni
    Shrestha, Ram Lal
    Sut, Stefania
    Ferri, Nicola
    Dall'Acqua, Stefano
    BIOORGANIC CHEMISTRY, 2022, 121
  • [46] AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
    Desai, Nihar R.
    Kohli, Payal
    Giugliano, Robert P.
    O'Donoghue, Michelle L.
    Somaratne, Ransi
    Zhou, Jing
    Hoffman, Elaine B.
    Huang, Fannie
    Rogers, William J.
    Wasserman, Scott M.
    Scott, Robert
    Sabatine, Marc S.
    CIRCULATION, 2013, 128 (09) : 962 - 969
  • [47] Reduction of low density lipoprotein- cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
    Ference, Brian A.
    Cannon, Christopher P.
    Landmesser, Ulf
    Luescher, Thomas F.
    Catapano, Alberico L.
    Ray, Kausik K.
    EUROPEAN HEART JOURNAL, 2018, 39 (27) : 2540 - 2545
  • [48] From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients
    Zenti, Maria G.
    Altomari, Anna
    Lupo, Maria G.
    Botta, Margherita
    Bonora, Enzo
    Corsini, Alberto
    Ruscica, Massimiliano
    Ferri, Nicola
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2018, 25 (17) : 1843 - 1851
  • [49] Dilignans with a Chromanol Motif Discovered by Molecular Networking from the Stem Barks of Magnolia obovata and Their Proprotein Convertase Subtilisin/Kexin Type 9 Expression Inhibitory Activity
    Ahn, Jongmin
    Chae, Hee-Sung
    Pel, Pisey
    Kim, Young-Mi
    Choi, Young Hee
    Kim, Jinwoong
    Chin, Young-Won
    BIOMOLECULES, 2021, 11 (03) : 1 - 14
  • [50] SAFETY AND EFFICACY OF PROPROTEIN CONVERTASE SUBTILISIN/ KEXIN TYPE 9 INHIBITORS AFTER ACUTE CORONARY SYNDROME; A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Atia, A.
    Wageeh, A.
    Aboeldahab, H.
    Elneny, M.
    Abdelwahab, M.
    Elmallahy, M.
    Aboelkhier, M.
    Elawfi, B.
    Sayed, S.
    Elrosasy, A.
    ATHEROSCLEROSIS, 2023, 379 : S78 - S80
12345